Crystalline form of a CDK inhibitor
The invention relates to a crystalline form of 6-(difluoromethyl)-8- [(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl) piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one (PF-06873600) free base (Form 1). The invention also relates to pharmaceutical compositions comprising this crysta...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
29.07.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention relates to a crystalline form of 6-(difluoromethyl)-8- [(1R,2R)-2-hydroxy-2-methylcyclopentyl]-2-{[1-(methylsulfonyl) piperidin-4-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one (PF-06873600) free base (Form 1). The invention also relates to pharmaceutical compositions comprising this crystalline form and to methods of using the crystalline form and such compositions for the treatment of abnormal cell growth, such as cancer, in a mammal. Formula (I): |
---|---|
Bibliography: | Application Number: AU20200209500 |